- Home
- DHAI vs NEUP Comparison
DHAI vs NEUP Comparison
Compare DHAI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- NEUP
- Stock Information
- Founded
- DHAI 2007
- NEUP 1996
- Country
- DHAI United States
- NEUP United States
- Employees
- DHAI N/A
- NEUP N/A
- Industry
- DHAI
- NEUP
- Sector
- DHAI
- NEUP
- Exchange
- DHAI NYSE
- NEUP Nasdaq
- Market Cap
- DHAI 11.6M
- NEUP 12.7M
- IPO Year
- DHAI N/A
- NEUP N/A
- Fundamental
- Price
- DHAI $0.27
- NEUP $8.50
- Analyst Decision
- DHAI
- NEUP Strong Buy
- Analyst Count
- DHAI 0
- NEUP 1
- Target Price
- DHAI N/A
- NEUP $21.00
- AVG Volume (30 Days)
- DHAI 2.6M
- NEUP 43.7K
- Earning Date
- DHAI 08-18-2025
- NEUP 08-15-2025
- Dividend Yield
- DHAI N/A
- NEUP N/A
- EPS Growth
- DHAI N/A
- NEUP N/A
- EPS
- DHAI N/A
- NEUP 0.00
- Revenue
- DHAI $69,573,000.00
- NEUP $15,662,715.00
- Revenue This Year
- DHAI N/A
- NEUP N/A
- Revenue Next Year
- DHAI N/A
- NEUP N/A
- P/E Ratio
- DHAI N/A
- NEUP $4,991.17
- Revenue Growth
- DHAI 5.40
- NEUP N/A
- 52 Week Low
- DHAI $0.12
- NEUP $2.90
- 52 Week High
- DHAI $3.25
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- DHAI 53.70
- NEUP N/A
- Support Level
- DHAI $0.24
- NEUP N/A
- Resistance Level
- DHAI $0.31
- NEUP N/A
- Average True Range (ATR)
- DHAI 0.03
- NEUP 0.00
- MACD
- DHAI 0.00
- NEUP 0.00
- Stochastic Oscillator
- DHAI 50.63
- NEUP 0.00
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.